Vaccine Breaking News

Vaccine breaking news brought to you by Precision Vaccinations.

Apr 3, 2021 • 12:00 pm CDT

The Pan American Health Organization (PAHO) confirmed as of week #12; there have been 175,372 suspected and confirmed dengue cases and 32 associated deaths reported in the Americas region during 2021.

All four dengue virus serotypes (DENV 1, DENV 2, DENV 3, and DENV 4) are currently circulating in the region of the Americas, which increases the risk of severe dengue cases.

The five countries reporting the most dengue cases are Brazil (130,013), Nicaragua (9,207), Peru (7,953), Colombia (7,247), Paraguay (6,938).

To alert international travelers of their dengue risk, the U.S.CDC issued a Level 1 Travel Alert for many parts of Central and South America, Mexico, and the Caribbean on March 2, 2021.

Furthermore, the CDC recently confirmed five dengue cases in the continental USA, with the US Territory of Puerto Rico reporting 85 dengue cases during 2021.

Dengue is a disease caused by a virus spread through mosquito bites. Health effects from dengue include fever, headache, nausea, vomiting, rash, muscle and joint pain, and minor bleeding.

Dengue can become severe within a few hours. Severe dengue is a medical emergency, usually requiring hospitalization. In severe cases, health effects can include hemorrhage, shock, organ failure, and death says the CDC.

The first approved dengue vaccine, known as Dengvaxia, is a recombinant yellow fever-17D–dengue virus, live, attenuated, tetravalent dengue vaccine, produced by Sanofi Pasteur, and was initially licensed for use in individuals aged from 9 to 45 years during 2016.

The U.S. FDA authorized the Dengvaxia vaccine for limited use in the USA on May 1, 2019, for people with laboratory-confirmed previous dengue infection and living in endemic areas.

There are several dengue vaccine candidates in various stages of a clinical study.

Medical Review by
Apr 2, 2021 • 3:39 pm CDT

The Global Polio Eradication Initiative confirmed on March 31, 2021, Afghanistan and Senegal reported polio cases over the last week involving circulating vaccine-derived poliovirus type 2 (cVDPV2).

And a map showing the latest number of polio cases in each affected country was updated.

Since the launch of the GPEI in 1988, it successfully decreased wild poliovirus cases by over 99%. 

Polio can be prevented with a vaccine. Since 2000, the inactivated polio vaccine (IPV) is most often given in the USA. It is administered by a shot in the arm or leg, depending on the person’s age, says the U.S. CDC.

The U.S. CDC's Advisory Committee on Immunization Practices Vaccine Recommendations is published on this webpage. Several U.S. FDA Authorized Polio Vaccines are listed on this Vax-Before-Travel webpage.

Medical Review by
Apr 2, 2021 • 3:01 pm CDT

The US Centers for Disease Control and Prevention (CDC) published a new study in the Morbidity and Mortality Weekly Report on April 2, 2021 that says 'interim vaccine effectiveness findings for both Pfizer-BioNTech and Moderna mRNA vaccines in real-world conditions complement and expand upon the vaccine effectiveness estimates from recent studies.

And these experimental COVID-19 vaccines demonstrate that current vaccination efforts result in substantial preventive benefits among working-age adults. They reinforce the CDC’s recommendation of full 2-dose immunization with mRNA vaccines.

This CDC study reviewed the findings of prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers who completed weekly SARS-CoV-2 testing for 13 consecutive weeks.

The eight locations that shared a common protocol and methods were Phoenix, Tucson, and other areas in Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah.

Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after the second dose) was 90% against the SARS-CoV-2 coronavirus.

infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after the first dose) before the second dose) was 80%.

It takes about two weeks following each dose of vaccine for the body to produce antibodies that protect against infection. As a result, people are considered “partially vaccinated” two weeks after their first dose of mRNA vaccine and “fully vaccinated” two weeks after their second dose.

'COVID-19 vaccination is recommended for all eligible persons, which currently varies by location in the USA,' said the CDC.

'The scientific rigor of these findings is enhanced by its prospective design and the participants’ very high adherence to weekly specimen collection. As the study progresses, viruses will be genetically characterized to examine the viral features of breakthrough infections. Given that there is uncertainty related to the number of days required to develop immunity postvaccination, future research examining vaccine effectiveness at different intervals is warranted, concluded this study.

All study authors completed and submitted the International Committee of Medical Journal Editors form to disclose potential conflicts of interest. No substantial industry conflicts of interest were disclosed.

Apr 2, 2021 • 12:45 pm CDT

The U.S. CDC and the World Health Organization (WHO) reported good news regarding the 2020-2021 flu season.

On April 2, 2021, the CDC's Key Updates for Week #12, ending March 27, 2021, stated 'seasonal influenza activity in the USA remains lower than usual for this time of year. This year is lower than rates for any flu season since routine data collection began in 2005.'

As an example, there has been (1) influenza-associated pediatric fatality reported to CDC this season. This data compares with the last flu season when 198 influenza-associated pediatric fatalities were confirmed.

Previously, on March 29, 2021, the WHO's Influenza Update #390 says 'Globally, despite continued or even increased testing for influenza in some countries, influenza activity remained at lower levels than expected for this time of the year.

In the Northern Hemisphere's temperate zone, influenza activity remained below baseline, though sporadic detections of influenza A and B viruses continued to be reported in some countries.

In the temperate zone of the Southern Hemisphere, influenza activity was reported at an inter-seasonal level.

And in the Caribbean and Central American countries, no influenza detections were reported.

The WHO says, 'The current influenza surveillance data should be interpreted with 'caution' as the ongoing COVID-19 pandemic has influenced to varying extents health-seeking behaviors around the world.'

Both the CDC and the WHO are already planning for the 2021-2020 flu season. These organizations have instructed the expected viruses flu shot producers can expect to confront. The detailed information is published on this webpage

Medical Review by
Apr 2, 2021 • 9:26 am CDT

New Brunswick-based Johnson & Johnson (J&J) confirmed today it is vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its experimental COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of J&J.

The randomized, double-blind, placebo-controlled Phase 2a study has been ongoing since September 2020.  and was initially designed to evaluate the safety, reactogenicity (expected reactions to vaccination in healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. This clinical study is now including adolescents 12 to 17 years of age.

The study’s goals are to evaluate reactogenicity and immunogenicity of two dose levels of the vaccine candidate and evaluate potential vaccination schedules at one, two, and three-month intervals in two-dose vaccine regimens in 1,210 adolescents aged 16-17 years.

Following the initial data review in this Phase 2a trial, the study will be expanded to a larger group of younger adolescents in a stepwise approach.

This trial is currently enrolling participants in Spain and the UK. Enrollment will commence shortly in the USA, the Netherlands, and Canada, with Brazil and Argentina to follow, says JnJ.

“Our COVID-19 vaccine candidate development program is designed to deliver on our commitment to protect people of all ages from this pandemic,” commented Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, J&J, in a press statement.

“In addition to expanding this ongoing study to include adolescents, we are in discussions with health authorities and are hard at work to initiate studies in pregnant women and children in the near future.”

The Janssen COVID-19 single-shot vaccine leverages Janssen's AdVac and PER.C6® technologies. Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease.

On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization allowing the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.

Medical Review by
Apr 2, 2021 • 7:46 am CDT

The World Health Organization (WHO) stated the 'current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, the WHO recommends that the drug only be used within clinical trials.'

This new WHO recommendation was issued on March 31, 2021, which applies to patients with COVID-19 of any disease severity.

This recommendation is now part of WHO’s guidelines on COVID-19 treatments.

Ivermectin is a broad-spectrum anti-parasitic agent, included in the WHO essential medicines list for several parasitic diseases. It is used to treat onchocerciasis (river blindness), strongyloidiasis, and other diseases caused by soil-transmitted helminthiasis. It is also used to treat scabies.

A guideline development group was convened in response to the increased international attention on ivermectin as a potential treatment for COVID-19. This group is an independent, international panel of experts, including clinical care experts in multiple specialties, and includes an ethicist and patient-partners.

The group reviewed pooled data from 16 randomized controlled trials (total enrolled 2407), including inpatients and outpatients with COVID-19. They determined that the evidence on whether ivermectin reduces mortality, need for mechanical ventilation, need for hospital admission, and time to clinical improvement in COVID-19 patients is of “very low certainty,” due to the small sizes and methodological limitations of available trial data, including a small number of events. 

The panel did not look at the use of ivermectin to prevent COVID-19, which is outside of the scope of the current guidelines.

Furthermore, the U.S. FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans.

'For one thing, animal drugs are often highly concentrated because they are used for large animals like horses and cows, which can weigh a lot more than we do—a ton or more. Such high doses can be highly toxic in humans,' says the FDA.

Ivermectin tablets are approved at precise doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an anti-viral (a drug for treating viruses).

Medical Review by
Apr 1, 2021 • 8:34 pm CDT

The U.S. Food and Drug Administration (FDA) announced on April 1, 2021, two revisions regarding the number of vaccine doses per vial available for the Moderna COVID-19 Vaccine.

The first revision clarifies the number of doses per vial for the currently available vials, in that the maximum number of extractable doses is 11, with a range of 10-11 doses.

The second revision authorizes the availability of an additional multi-dose vial. Each vial contains a maximum of 15 doses, with a range of 13-15 doses that can potentially be extracted.

“Both of these revisions positively impact the supply of Moderna COVID-19 Vaccine, which will help provide more vaccine doses to communities and allow shots to get into arms more quickly. Ultimately, more vaccines getting to the public in a timely manner should help bring an end to the pandemic more rapidly,” stated Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, in a press release.

Depending on the type of syringes and needles used to extract each dose, there may not be sufficient volume to extract more than 10 doses from the vial containing a maximum of 11 doses or more than 13 doses from the vial containing a maximum of 15 doses, says the FDA.

Because the Moderna COVID-19 Vaccine does not contain preservatives, any further remaining product that does not constitute a full dose should not be pooled from multiple vials to create one full dose. 

The vaccine dosing regimen remains unchanged; the vaccine is administered as a two-dose series, 0.5 mL each dose, one month apart.

The FDA is an agency within the U.S. Department of Health and Human Services that protects public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use and medical devices.

Medical Review by
Apr 1, 2021 • 5:33 pm CDT

Measles is once again on the rise in the Democratic Republic of Congo (DRC), reported the Médecins Sans Frontières (MSF) on March 31, 2021. The recent upsurge has exceeded 13,000 measles cases since January 1st.

Previously, between 2018 and 2020, the worst measles epidemic ever recorded in DRC tore through the country. In just two years, more than 460,000 children contracted measles, and nearly 8,000 died from it.

Most of these fatalities were children under five years of age.

“Unfortunately, since the end of 2020, several provinces have started recording new increases in patients with measles, notably the North and South Ubangi provinces,” says Anthony Kergosien, coordinator of MSF’s emergency response team in the DRC. "We had to urgently send mobile response teams again to help stem the progression and save as many lives as possible."

"Since we arrived in Bosobolo in mid-February, we have been helping staff to care for their patients in eight health centers and in the general hospital to which complicated cases are referred," explains Faustin Igulu, who is leading the MSF project in Bosobolo.

“More than 1,200 patients have already been treated thanks to our support,” he adds. "The hospital’s capacity had been quickly overwhelmed, so we increased the number of beds where they could treat children, some of whom were in a very advanced stage of measles and associated malnutrition."

A nurse at the Bosobolo General Referral Hospital is providing care to a young patient with measles. North Ubangi, Democratic Republic of Congo, February 2021.

MSF also launched a vaccination campaign for 66,000 children in this isolated health zone, and the work is ongoing with a focus on those living in hard-to-reach areas of the DRC.

'Our teams also trained local health workers in disease surveillance to improve the early detection of new measles outbreaks. However, like many other health zones in DRC, the resources available to local health authorities fall far short of what is needed' says the MSF.

The DRC (Zaire) is located in central sub-Saharan Africa with a population of about 86 million.

Measles is a viral disease spread by coughing, sneezing, or direct contact with nasal or laryngeal secretions.

Children with the disease can face severe complications, as measles ‘erase’ their immune memory, putting their health and lives at risk for years to come.

This immunity reduction creates even greater risks from local, ongoing outbreaks of the Ebola virusCOVID-19, and Polio.

The U.S. CDC says, 'Be aware of current health issues in the Democratic Republic of the Congo. Learn how to protect yourself. Check the travel vaccines and medicines list and visit your doctor at least a month before your trip.'

Médecins Sans Frontières translates to Doctors without Borders. MSF was founded in 1971 in Paris. Today, it is a worldwide movement of nearly 65,000 people.

Medical Review by
Apr 1, 2021 • 3:21 pm CDT

As The Lancet Infectious Diseases went to press on April 1, 2021, the Republic of Cuba was due to launch a phase 3 clinical trial of its subunit conjugate vaccine against COVID-19, known as Soberana-2 (FINLAY-FR-2).

A second phase 3 trial of the Soberana-2 vaccine is planned for Iran as part of a partnership between the Finlay Institute and the Pasteur Institute of Iran.

Based on as-yet-unpublished results from early-stage clinical trials, Vicente Verez-Bencomo, director-general of the Finlay Institute, expects the vaccine to show vaccine efficacy in the region of 80–95%, reported The Lancet. If everything goes according to plan, Cuba could start a mass vaccination program for its 11 million citizens sometime in the summer of 2021, reported Talha Burki.

“We are very optimistic,” Verez-Bencomo commented.

The Finlay Institute in Havana produces the Soberana 02 vaccine candidate.

If Soberana-2's clinical trials prove successful, Cuba plans to export it at a low cost after meeting national vaccination efforts. Verez-Bencomo reckons that by the end of the summer Cuba would have the capacity to produce 10 million vaccine doses per month, reported The Lancet.

Apr 1, 2021 • 10:36 am CDT

The U.S. Food and Drug Administration (FDA) announced on March 31, 2021, new authorizations of several tests for over-the-counter (OTC) use without a prescription when used for coronavirus serial screening.

In addition to the tests authorized for OTC use, one serial screening test was authorized for use in a point-of-care (POC) setting without a prescription, and an additional screening test was authorized for POC use with a prescription.

The addition of the OTC and POC tests for screening will offer schools, workplaces, communities, and others several options for serial screening tests that are accurate and reliable.

“Screening testing, especially with the over-the-counter tests authorized today, is an important part of the country’s pandemic response—many schools, workplaces, communities, and other entities are setting up testing programs to quickly screen for COVID-19," stated Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health, in a press statement.

"With the FDA’s authorization of multiple tests, the public can be assured these tests have met our scientific standards for emergency use authorization. As we’ve said all along, if it’s a good test, we’ll authorize it,”

“The FDA has taken many steps to support test development throughout the pandemic, including authorizing tests quickly, offering many avenues for test developers to work with us to get their tests on the market, if shown to be accurate and reliable, and issuing enforcement policies for COVID-19 tests."

"As the pandemic has progressed, we have worked with test developers wishing to add screening claims," concluded Dr. Shuren's comments.

As of March 31, 2021, the U.S. CDC reported about 371 million RT-PCR diagnostic tests, excluding antibody and antigen tests, have been performed to confirm SARS-CoV-2 virus infections during the COVID-19 pandemic.

The specific tests authorized by the FDA this week are as follows:

  • Quidel QuickVue At-Home OTC COVID-19 test - authorized for OTC at-home serial screening
  • Abbott BinaxNOW (multiple configurations)
  • Abbott BinaxNOW COVID-19 Antigen Self Test – authorized for OTC at-home serial screening
  • Abbott BinaxNOW COVID-19 Ag Card 2 Home Test - authorized for OTC at-home serial screening with telehealth proctor
  • Abbott BinaxNOW COVID-19 Ag 2 Card – authorized for POC serial screening without a prescription 
  • BD Veritor System for Rapid Detection of SARS-CoV-2 – authorized for POC serial screening with a prescription

These tests had been previously authorized by the FDA (some under different names) to test those with COVID-19 symptoms. Still, the actions this week authorize testing of asymptomatic individuals when used for serial testing.

As of March 30, 2021, the FDA announced it had authorized 349 coronavirus diagnostic tests, including 258 molecular tests, 74 antibody tests, and 17 antigen tests during the COVID-19 pandemic. Furthermore, 42 molecular authorizations can be used with home-collected samples.

The FDA is an agency within the U.S. Department of Health and Human Services that protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use and medical devices. 

Medical Review by
Apr 1, 2021 • 8:48 am CDT

Brazil's Collegiate Board of Anvisa announced its approval for temporary authorization for the Janssen COVID19 Vaccine's emergency use on March 31, 2021.

Brazil's federal health regulator Anvisa concluded, 'after analyzing the studies presented, that the vaccine protects against the severe form of the disease and is effective for preventing COVID-19 in adult patients.'

The Janssen vaccine is already authorized, on an emergency or provisional basis, in several countries, such as the United States (2/27/21) and Canada (3/5/2021), in addition to Europe (11/3/2021). In the same vein, the World Health Organization recently recommended the Janssen vaccine's emergency use in all countries.

"With the approval of this vaccine, Brazil ranks among the countries in the world that have the largest number of approved vaccine protocols. This demonstrates the Agency's commitment to promoting and protecting the health of the population. This protection and promotion mean evaluating with the necessary criteria and considering the exceptionality that the moment demands, the processes that are submitted to Anvisa," stated Romison Rodrigues, director of the Fourth Board, in a press release.

Developed by Janssen, the pharmaceutical arm of Johnson & Johnson, the single-shot experimental vaccine leverages Janssen's AdVac and PER.C6® technologies. 

Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease. Adenoviruses are a group of viruses that can cause the common cold.

Medical Review by
Apr 1, 2021 • 7:30 am CDT

Maryland-based Altimmune, Inc. announced clinical trial data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in (42) healthy volunteers.

In contrast to the currently licensed vaccine that requires three injected doses of vaccine over one month for protection, NasoShield is being developed as a single-dose, intranasal anthrax vaccine.

The clinical data from the Phase 1b trial showed that Serum binding antibody responses to the protective antigen of Bacillus anthracis, the bacterium and causative agent of anthrax, was significantly greater than in the placebo arm; Antibody responses blocking anthrax toxin were blunted compared to protective antigen-antibody responses and were low compared to prior studies conducted with BioThrax®, the only approved anthrax vaccine.  

Notably, as with Altimmune’s other intranasally administered replication-deficient adenovirus vaccines, nasal mucosal IgA responses specific for protective antigen were observed in up to 80% of subjects post-vaccination.

The NasoShield product characteristics may also provide for greatly improved logistics in distribution and administration, allowing it to be used more effectively than the currently approved vaccine in the event of an anthrax incident, stated the company's press release.

Altimmune is a clinical-stage biopharmaceutical company focused on developing intranasal vaccines, immune-modulating therapies, and treatments for liver disease. 

Medical Review by
Apr 1, 2021 • 6:35 am CDT

 Pfizer Inc. and Germany-based BioNTech SE announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19.

These results were measured seven days through up to six months after the second dose.

Furthermore, the experimental vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration.

Safety data from the Phase 3 study has also been collected from more than 12,000 vaccinated participants who have a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile.

“It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up,” commented Ugur Sahin, CEO, and Co-founder of BioNTech, in a press release.

“These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population.”

The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization for active immunization to prevent COVID-19 caused by the SARS-CoV-2 coronavirus in individuals 16 years of age and older.

This vaccine's name in Europe is Comiranty.

Medical Review by
Mar 31, 2021 • 7:49 pm CDT

Since January of 2020, Johnson & Johnson has been working directly with governments, health authorities, and other companies to help end the global pandemic. We continue to expect to deliver our COVID-19 vaccine at a rate of more than one billion doses by the end of 2021, stated a press release issued on March 31, 2021.

'We are pleased we have met our commitment to deliver enough single-shot vaccines (Janssen COVID-19) by the end of March to enable the full vaccination of more than 20 million people in the United States. This is part of our plan to deliver 100 million single-shot vaccines to the U.S. during the first half of 2021, aiming to deliver those doses by the end of May.'

'As with the manufacturing of any complex biologic medication or vaccine, the start-up for a new process includes test runs and quality checks to ensure manufacturing is validated and the end product meets our high-quality standards. This approach includes having dedicated specialists on the ground at the companies that are part of our global manufacturing network to support safety and quality.'

'This quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorized to manufacture drug substance for our COVID-19 vaccine.'

'This batch was never advanced to the filling and finishing stages of our manufacturing process.'

The issue was identified and addressed with Emergent and shared with the United States Food & Drug Administration (FDA).

Quality and safety continue to be our top priority. Therefore, as we continue to work with FDA and Emergent toward the Emergency Use Authorization of the Emergent Bayview Facility,

Johnson & Johnson is providing additional experts in manufacturing, technical operations, and quality to be on-site at Emergent to supervise, direct and support all manufacturing of the Johnson & Johnson COVID-19 vaccine. In coordination with the U.S. Department of Health & Human Services, these steps will enable us to safely deliver an additional 24 million single-shot vaccine doses through April 2021.'

The Johnson and Johnson Janssen COVID-19 single-shot experimental vaccine leverages Janssen's AdVac and PER.C6® technologies. Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease. Adenoviruses are a group of viruses that can cause the common cold.

Medical Review by
Mar 31, 2021 • 7:29 pm CDT

Tübingen-based CureVac N.V. and Celonic Group announced a partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

The parties entered into a commercial supply agreement to produce CureVac’s coronavirus vaccine candidate at Celonic’s state-of-the-art commercial manufacturing facility for biologics and ATMPs, in Heidelberg, Germany.

In total, Celonic will manufacture more than 100 million vaccine doses of CVnCoV, with more than 50 million doses expected to be produced before the end of 2021.

Furthermore, CureVac reaffirmed in the press statement issued on March 30, 21, the expected output capacity of its broad European manufacturing network of up to 300 million doses in 2021.

“Since the onset of the pandemic, Celonic has committed extensive breadth of complex bio-solutions development expertise and manufacturing resources to this global challenge,” added Dr. Konstantin Matentzoglu, CEO of Celonic.

“We have invested heavily to support our partners in bringing novel COVID-19 therapeutics and vaccines to patients at an accelerated pace. Celonic is proud to collaborate with CureVac as part of an expansive manufacturing network in this global fight against COVID-19 by contributing to its mRNA-based COVID-19 vaccine candidate, CVnCoV.

Celonic, a global contract development & manufacturing organization for innovative biopharmaceuticals, including cell and gene therapy products, is part of the private and independent family-owned company JRS-Group, with currently two production sites; in Basel, Switzerland (HQ) and Heidelberg, Germany.